- Scangos George A, President & CEO: reported buying $80.00K

- Willsey Lance, Director: reported buying $169.95K

Over the last four weeks insiders at Exelixis Inc (EXEL) have bought more than $1.28M:

- Papadopoulos Stelios, Director: bought $968.83K increasing total holdings by 46%

- Karbe Frank, EVP, CFO: bought $57.38K increasing total holdings by 257%

- Willsey Lance, Director: bought $169.95K increasing total holdings by 133%

- Scangos George A, President & CEO: bought $80.00K increasing total holdings by 2%

For a current, real-time summary of EXEL insider activity, visit http://www.form4oracle.com/company?cik=0000939767&ticker=EXEL

About Form4Oracle

Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com.

About Exelixis Inc

Exelixis, Inc., a development-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. Its product pipeline includes approximately 10 investigational compounds in Phase II and Phase I clinical development. The company?s lead compounds, which are in Phase II clinical trial include XL647 that inhibits EGFR, HER2, and VEGFR, which are receptor tyrosine kinases (RTKs) implicated in driving tumor proliferation and vascularization; and XL184, which inhibits the MET, RET, and VEGFR RTKs, is being developed for the treatment of medullary thyroid cancer and other tumor types. Its product portfolio also comprises XL019 that specifically inhibits the JAK2 tyrosine kinase and is being developed for the treatment of myelofibrosis, a myeloproliferative disorder. Exelixis has strategic corporate alliances with various pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. The company was founded in 1994. It was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis is headquartered in South San Francisco, California.

--------------------------------------------

The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard.

Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein.

CONTACT: Kimberly Sutton, on behalf of Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

- Dean Steven G, Sr VP, Chief Financial Officer: bought $15.09K increasing total holdings by 22%

- Dowdell Douglas L, Sr VP, Specialty Fibers: bought $184.79K increasing total holdings by 155%

For a current, real-time summary of BKI insider activity, visit http://www.form4oracle.com/company?cik=0000899597&ticker=BKI

About Form4Oracle

Form4Oracle, LLC specializes in distributing insider trading information published by the SEC, making it accessible and actionable for all types of investors. To learn more about how tracking insider trading activity can improve your investment returns, visit http://www.form4oracle.com.

About Buckeye Technologies Inc

Buckeye Technologies, Inc. manufactures and distributes cellulose-based specialty products made from wood and cotton worldwide. The company?s products include chemical cellulose, customized fibers, fluff pulp, and nonwoven materials. Its chemical cellulose is used in the manufacture of various products, including food casings, cigarette filters, rayon filament, acetate fibers, and thickeners for consumer products, cosmetics, and pharmaceuticals. The company?s customized fibers are used to provide porosity, color permanence, and tear resistance in filters, letterheads, currency paper, and personal stationery, as well as absorbency and softness in cotton balls and cotton swabs. Its fluff pulp and nonwoven materials are used to increase absorbency and fluid transport in products, such as disposable diapers, feminine hygiene products, and adult incontinence products, as well as used to enhance fluid management and strength in wipes, tabletop items, food pads, household wipes, and mops. The company was founded in 1992 and is headquartered in Memphis, Tennessee.

--------------------------------------------

The companies referenced in this report have not approved the statements made in this report. This report contains statements that imply risks and uncertainties. This material is for informational reporting purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Form4Oracle is not a licensed broker, broker dealer, market maker, investment banker, investment adviser, analyst or underwriter and is not compensated in this regard.

Please consult your broker to understand investing benefits and risks and prior to purchasing any securities mentioned herein.

CONTACT: Kimberly Sutton, Form4Oracle Tel: +1 312 315 5077 e-mail: kimberly@form4oracle.com WWW: http://www.form4oracle.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.